| Regulation of G1 cell cycle progression: distinguishing the restriction point from a nutrient-sensing cell growth checkpoint (s) DA Foster, P Yellen, L Xu, M Saqcena Genes & cancer 1 (11), 1124-1131, 2010 | 313 | 2010 |
| Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine J Nagarajah, M Le, JA Knauf, G Ferrandino, C Montero-Conde, ... The Journal of clinical investigation 126 (11), 4119-4124, 2016 | 124 | 2016 |
| Phospholipase D mediates nutrient input to mammalian target of rapamycin complex 1 (mTORC1) L Xu, D Salloum, PS Medlin, M Saqcena, P Yellen, B Perrella, DA Foster Journal of Biological Chemistry 286 (29), 25477-25486, 2011 | 118 | 2011 |
| High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1 P Yellen, M Saqcena, D Salloum, J Feng, A Preda, L Xu, ... Cell Cycle 10 (22), 3948-3956, 2011 | 116 | 2011 |
| Amino acids and mTOR mediate distinct metabolic checkpoints in mammalian G1 cell cycle M Saqcena, D Menon, D Patel, S Mukhopadhyay, V Chow, DA Foster PloS one 8 (8), e74157, 2013 | 94 | 2013 |
| Drosophila insulin and target of rapamycin (TOR) pathways regulate GSK3 beta activity to control Myc stability and determine Myc expression in vivo F Parisi, S Riccardo, M Daniel, M Saqcena, N Kundu, A Pession, D Grifoni, ... BMC biology 9, 1-13, 2011 | 73 | 2011 |
| Tipifarnib inhibits HRAS-driven dedifferentiated thyroid cancers BR Untch, V Dos Anjos, MER Garcia-Rendueles, JA Knauf, ... Cancer Research 78 (16), 4642-4657, 2018 | 67 | 2018 |
| EIF1AX and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and c-MYC GP Krishnamoorthy, NR Davidson, SD Leach, Z Zhao, SW Lowe, G Lee, ... Cancer Discovery 9 (2), 264-281, 2019 | 66 | 2019 |
| SWI/SNF complex mutations promote thyroid tumor progression and insensitivity to redifferentiation therapies M Saqcena, LJ Leandro-Garcia, JLV Maag, V Tchekmedyian, ... Cancer Discovery 11 (5), 1158-1175, 2021 | 63 | 2021 |
| Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs M Saqcena, S Mukhopadhyay, C Hosny, A Alhamed, A Chatterjee, ... Oncogene 34 (20), 2672-2680, 2015 | 63 | 2015 |
| Reciprocal regulation of AMP-activated protein kinase and phospholipase D. S Mukhopadhyay, M Saqcena, A Chatterjee, A Garcia, MA Frias, DA Foster Journal of Biological Chemistry, 2015 | 58 | 2015 |
| Synthetic lethality in KRas-driven cancer cells created by glutamine deprivation S Mukhopadhyay, M Saqcena, DA Foster Oncoscience 2 (10), 807, 2015 | 46 | 2015 |
| Identification of domains responsible for ubiquitin-dependent degradation of dMyc by glycogen synthase kinase 3β and casein kinase 1 kinases M Galletti, S Riccardo, F Parisi, C Lora, MK Saqcena, L Rivas, B Wong, ... Molecular and cellular biology 29 (12), 3424-3434, 2009 | 43 | 2009 |
| Apoptotic effects of high-dose rapamycin occur in S-phase of the cell cycle M Saqcena, D Patel, D Menon, S Mukhopadhyay, DA Foster Cell Cycle 14 (14), 2285-2292, 2015 | 34 | 2015 |
| A late G1 lipid checkpoint that is dysregulated in clear cell renal carcinoma cells D Patel, D Salloum, M Saqcena, A Chatterjee, V Mroz, M Ohh, DA Foster Journal of Biological Chemistry 292 (3), 936-944, 2017 | 27 | 2017 |
| Characterization of Subtypes of BRAF-Mutant Papillary Thyroid Cancer Defined by Their Thyroid Differentiation Score L Boucai, V Seshan, M Williams, JA Knauf, M Saqcena, RA Ghossein, ... The Journal of Clinical Endocrinology & Metabolism 107 (4), 1030-1039, 2022 | 20 | 2022 |
| Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers KA Luckett, JR Cracchiolo, GP Krishnamoorthy, LJ Leandro-Garcia, ... Endocrine-Related Cancer 28 (6), 391-402, 2021 | 15 | 2021 |
| Genomic and transcriptomic characteristics of metastatic thyroid cancers with exceptional responses to radioactive iodine therapy L Boucai, M Saqcena, F Kuo, RK Grewal, N Socci, JA Knauf, ... Clinical Cancer Research 29 (8), 1620-1630, 2023 | 14 | 2023 |
| Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors MER Garcia-Rendueles, G Krishnamoorthy, M Saqcena, A Acuña-Ruiz, ... Molecular Cancer 21 (1), 213, 2022 | 11 | 2022 |
| RBM10 loss in thyroid cancer leads to aberrant splicing of cytoskeletal and extracellular matrix mRNAs and increased metastatic fitness GP Krishnamoorthy, A Glover, B Untch, M Saqcena, D Vukel, K Berman, ... Cancer Research 82 (12_Supplement), 986-986, 2022 | 3 | 2022 |
